Stromal myofibroblasts in breast cancer: Relations between their occurrence, tumor grade and expression of some tumour markers

Folia Histochemica et Cytobiologica

Volumn 44, Issue 2, 2006, Pages 111-116

  Surowiak, Paweł ^a,b,c   Suchocki, Sławomir ^d   Györffy, Balazs ^b,e   Gansukh, Tserenchunt ^b,f   Wojnar, Andrzej ^c   Maciejczyk, Adam ^c   Pudełko, Marek ^c   Zabel, Maciej ^a,g  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Charité Campus Benjamin Franklin Medical Center   (Germany)

^c Wroclaw   (Poland)

^d Voivodship Hospital   (Poland)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f MONGOLIAN NATIONAL UNIVERSITY OF MEDICAL SCIENCES   (Mongolia)

^g POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Breast cancer; Grade; HER 2; Ki67; Myofibroblasts; P53

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PARAFFIN; PROTEIN P53; SMOOTH MUSCLE ACTIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER GRADING; CELL COMPOSITION; CELL COUNT; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MYOFIBROBLAST; PROGNOSIS; PROTEIN EXPRESSION; STROMA; TISSUE SECTION;

EID: 33646418702     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Chaponnier C, Gabbiani G (2004) Pathological situations characterized by altered actin isoform expression. J Pathol 204: 386-395
2. De Wever O, Mareei M (2003) Role of tissue stroma in cancer cell invasion. J Pathol 200: 429-447
3. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 5: 403-410
4. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connoly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 966-978
5. Jemal A, Thomas A, Murray T, Thun M (2002) Cancer statistics. CA Cancer J Clin 52: 23-47
6. Mori I, Yang Q, Kakudo K (2002) Predictive and prognostic markers for invasive breast cancer. Pathol Inst 52: 186-194
7. Offersen BV, Nielsen BS, Hoyer-Hansen G, Rank F, Hamilton-Dutoit S. Overgaard J, Andreasen PA (2003) The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol 163: 1887-1899
8. Sobin LH, Wittekind C (2002) TNM classification of malignant tumours. 5th edition. Wiley-Liss INC., New York
9. Surowiak P, Dziegiel P, Matkowski R, Kornafel J, Wojnar A, Zabel M (2002) Immunocytochemical evaluation of metallothionein (MT) expression in myoepithelial cells of ductal mammary carcinoma and its relation to survival time: analysis of 7-year course of the disease. Folia Histochem Cytobiol 40: 199-200
10. Surowiak P, Dziegiel P, Zabel M, Matkowski R, Kornafel J (2001) Prognostic value of immunocytochemical estimation of estrogen receptor (ER) and of pS2 estrogen-dependent protein in cells of mammary ductal carcinoma. Analysis of five-year course of the disease. Folia Histochem Cytobiol 39: 143-144
11. Yazhou C, Wenlv S, Weidong Z, Licun W (2004) Clinicopathological significance of stromal myofibroblasts in invasive ductal carcinoma of the breast. Tumor Biol 25: 290-296
12. Zasławski R, Surowiak P, Paluchowski P, Dziegiel P, Maciejczyk A, Pudełko M, Wojnar A, Zabel M (2005) Differences in oestrogen and progesterone receptors, HER-2, p53 expression and proliferation in ductal breast cancers in relation to histopathological grade. Folia Morphol 64: 9-15